Clinical trials: MTOR
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.
- Trial name
- EXIST-2 (NCT00790400)
- Testing
- Everolimus (RAD001)
- Where
- 25 sites in United States, Canada and 9 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Locally Advanced Cervical Cancer
A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer
The cervix cancer is the second malignant neoplasia more common between women. The combined treatment involving chemotherapy and radiotherapy was defined as the standard.
- Trial name
- PHOENIX I (NCT01217177)
- Testing
- everolimus
- Where
- 2 sites in Brazil
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Tuberous Sclerosis, Lymphangioleiomyomatosis
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
The purpose of this research study is to find out what effects RAD001 has on angiomyolipomas of a person with Tuberous Sclerosis Complex and to determine the safe dose of RAD001 without toxicity.
- Trial name
- NCT00457964
- Testing
- RAD001
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cancer
Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer
mTOR kinase is part of the mTORC1 complex that promotes cap-dependent protein translation, and part of the mTORC2 complex that activates AKT.
- Trial name
- NCT02306135
- Testing
- n/a- this is an observational study
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Prostate Cancer, Adenocarcinoma of the Prostate
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Temsirolimus and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus together with vorinostat may kill more tumor cells.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01174199
- Testing
- vorinostat, temsirolimus, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Roswell Park Cancer Institute
Inoperable Locally Advanced Breast Cancer, Metastatic Breast Cancer (MBC)
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
This is a prospective, multi-center, open-label, phase Ib/ II study (two parts) with patients that have locally advanced or metastatic HER2 negative breast cancer.
- Trial name
- NCT01495247
- Testing
- BEZ235, Paclitaxel
- Where
- 3 sites in France, Spain
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models.
- Trial name
- NCT02587325
- Testing
- nab-sirolimus
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aadi Bioscience, Inc.
Breast Cancer Metastatic, Renal Cell Carcinoma (RCC)
Sapu003 in Advanced mTOR-sensitive Solid Tumors
This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced mTOR-sensitive solid tumors (HR+/HER2-negative…
- Conditions
- Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC)
- Trial name
- NCT07369505
- Testing
- Sapu003, Exemestane 25 MG
- Where
- Australia
- Volunteers
- 27 people
- Sponsor
- SAPU NANO (US) LLC
Neurofibromatosis 1
Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
This trial is evaluating the use of oral Everolimus to determine if there is a reduction in the size of the disfiguring cutaneous lesions in patients with Neurofibromatosis 1 over a 6 month period.
- Trial name
- DCLNF1 (NCT02332902)
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center, Houston
Pancreatic Neuroendocrine Tumors (pNET)
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
This is a Phase II study in 2 stages, evaluating BEZ235 plus best supportive care (BSC) versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy.
- Trial name
- NCT01658436
- Testing
- BEZ235 (Stage 1)
- Where
- 17 sites in United States, Austria and 7 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Endometrium Cancer, Tumor Infiltration
Tumor-Infiltrating Lymphocytes in Endometrial Cancer
Endometrial cancer (EC) is a leading cancer among women globally. The tumor microenvironment in EC is characterized by complex interactions between cancer cells and immune components.
- Trial name
- NCT06976333
- Testing
- Tumor-infliltrating lymphocyte (TIL) percentage, Grey level co-occurrence matrix (GLCM), Fractal dimension (FD)
- Where
- Poland
- Volunteers
- 52 people
- Sponsor
- Jagiellonian University
Renal Cell Cancer, Cancer
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers
In the present study the investigators want to explore the safety, pharmacokinetics, and activity of the combination of temsirolimus and nelfinavir, both agents with PI3K /Akt/mTOR inhibiting activity, in patients with advanced…
- Trial name
- I-NET (NCT01079286)
- Testing
- Nelfinavir and temsirolimus
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Estrogen Receptor Positive Breast Cancer
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
This is an open label phase II clinical trial to determine the efficacy, toxicity, and safety of TAK-228 plus tamoxifen in patients with newly diagnosed ER-positive, HER2-negative breast cancer.
- Trial name
- ANETT (NCT02988986)
- Testing
- TAK-228, Tamoxifen
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- The Methodist Hospital Research Institute
Aging, Insulin Resistance
Everolimus Aging Study
The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans.
- Trial name
- EVERLAST (NCT05835999)
- Testing
- Everolimus 0.5 MG once per day, Everolimus 5 MG once per week
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Hepatitis C Recurrence After Liver Transplant
The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
Background: Hepatitis C recurrence, which invariably occurs in viremic liver transplant (LT) recipients, associated with accelerated liver fibrosis leading to established graft cirrhosis in 40-20% of patients in 5 years with…
- Trial name
- NCT01707849
- Testing
- EVL arm, MMF arm
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Hospital Vall d'Hebron
Renal Transplant
mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation
This study is designed to evaluate efficacity and safety of everolimus or (cyclosporine then everolimus) vs. cyclosporine as immunosuppressive treatment in renal transplantation for elderly (>60 years old) recipients receiving…
- Trial name
- EVEROLD (NCT01028092)
- Testing
- Anti R-IL2 + Cyclosporine, Thymoglobulin + Everolimus, Anti R-IL2 + Cyclosporine then Everolimus
- Where
- 18 sites in France
- Volunteers
- 327 people
- Sponsor
- University Hospital, Brest
Muscle Atrophy, Age-Related Sarcopenia
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)
As people age, muscle mass and function is lost and exercise training is an important way to reduce the effects of this and remain independent.
- Trial name
- Rapamune (NCT05414292)
- Testing
- Rapamune (sirolimus) 1Mg Tablet, Unilateral resistance exercise training
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Advanced Cancers
Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)
To describe the long-term safety of deforolimus (ridaforolimus, MK-8669) in participants for whom a clinical benefit has been established in a prior parent trial (MK-8669-013, NCT00060645; MK-8669-016, NCT00112372; and…
- Trial name
- NCT00836927
- Testing
- Ridaforolimus Tablet, Ridaforolimus Intravenous (IV) Infusion
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
Peutz-Jeghers Syndrome
Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome
Pilot study, Open-label, Phase II study of Everolimus. Objective: To determine if Everolimus can diminish large gastrointestinal polyps in patients with Peutz-Jeghers Syndrome.
- Trial name
- NCT00811590
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Utah
Malignant Mesothelioma
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with pleural malignant…
- Trial name
- NCT00770120
- Testing
- everolimus
- Where
- 129 sites in United States
- Volunteers
- 61 people
- Sponsor
- SWOG Cancer Research Network